Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating mutations an attractive drug target because they are probable driver mutations of this disease. As more potent FLT3...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Galanis, Allison, Ma, Hayley, Rajkhowa, Trivikram, Ramachandran, Abhijit, Small, Donald, Cortes, Jorge, Levis, Mark
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3879910/
https://ncbi.nlm.nih.gov/pubmed/24227820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-10-529313
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares